VaxOnco moves multi-epitope vaccine for malaria into the clinic
This article was originally published in Scrip
Executive Summary
VaxOnco, a South Korean company developing peptide-based vaccines mainly for cancer indications, has begun a US Phase I clinical trial with a DNA-based multi-epitope vaccine against malaria.